Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;78(1):40-46.e7.
doi: 10.1016/j.jaad.2017.08.039. Epub 2017 Oct 17.

Determination of the impact of melanoma surgical timing on survival using the National Cancer Database

Ruzica Z Conic  1 , Claudia I Cabrera  1 , Alok A Khorana  2 , Brian R Gastman  3
Affiliations

Determination of the impact of melanoma surgical timing on survival using the National Cancer Database

Ruzica Z Conic et al. J Am Acad Dermatol. 2018 Jan.

Abstract

Background: The ideal timing for melanoma treatment, predominantly surgery, remains undetermined. Patient concern for receiving immediate treatment often exceeds surgeon or hospital availability, requiring establishment of a safe window for melanoma surgery.

Objective: To assess the impact of time to definitive melanoma surgery on overall survival.

Methods: Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (N = 153,218). The t test and chi-square test were used to compare variables. Cox regression was used for multivariate analysis.

Results: In a multivariate analysis of patients in all stages who were treated between 90 and 119 days after biopsy (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.18) and more than 119 days (HR, 1.12; 95% CI, 1.02-1.22) had a higher risk for mortality compared with those treated within 30 days of biopsy. In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days (HR, 1.05; 95% CI, 1.01-1.1), 60 to 89 days (HR, 1.16; 95% CI, 1.07-1.25), 90 to 119 days (HR, 1.29; 95% CI, 1.12-1.48), and more than 119 days after biopsy (HR, 1.41; 95% CI, 1.21-1.65). Surgical timing did not affect survival in stages II and III.

Limitations: Melanoma-specific survival was not available.

Conclusion: Expeditious treatment of stage I melanoma is associated with improved outcomes.

Keywords: National Cancer Database; melanoma; stage I melanoma; survival; time to surgery; time to treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

Figures

Fig 1
Fig 1
Flowchart presenting selection of patients from the National Cancer Database.
Fig 2
Fig 2
Graphic representation of adjusted and unadjusted hazard ratios by time to treatment initiation. Point estimates represent hazard ratios. Bars represent 95% confidence intervals. A, Unadjusted hazard ratios by time to treatment initiation. B, Unadjusted hazard ratio for days to treatment in stage I. C, Unadjusted hazard ratio for days to treatment in stage II. D, Unadjusted hazard ratio for days to treatment in stage III. Asterisks denote statistical significance.
Fig 3
Fig 3
Graphic representation of adjusted hazard ratios by time to treatment initiation. Point estimates represent hazard ratios. Bars represent 95% confidence intervals. A, Adjusted hazard ratios by time to treatment initiation. B, Adjusted hazard ratio for days to treatment in stage I. C, Adjusted hazard ratio for days to treatment in stage II. D, Adjusted hazard ratio for days to treatment in stage III. Asterisks denote statistical significance.
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Georgia: American Cancer Society; 2016. [Accessed July 6, 2016]. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
    1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975–2013. [Accessed June 10, 2016]. Available at: https://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
    1. Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2014;170:11–19. - PubMed
    1. Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in northern Germany. J Am Acad Dermatol. 2012;66:201–211. - PubMed

MeSH terms